CMS has given plan sponsors the flexibility to choose which drug therapy categories they’d like to administer the Part B step on, explained Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors,
CMS has given plan sponsors the flexibility to choose which drug therapy categories they’d like to administer the Part B step on, explained Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors,
Transcript
CMS is proposing allowing step therapy in Medicare Advantage plans for Part B drugs. Which drugs will this impact, and how will patients be affected?
The beauty of it all is that CMS really has given plan sponsors flexibility to choose which drug therapy categories they’d like to administer the Part B step on, and ideally, when you start thinking about good candidates to be a part of a step therapy, you want to look at drug therapy categories that have quite a few agents in them that have similar efficacy to really help you to be able to decide where can you really kick this off. I think the other thing to take into consideration is that plans are still going to be held by those local coverage determinations and national coverage determinations, so they do need to keep that in mind.
But, if I have to use my crystal ball and think about what might be a good therapeutic category, obviously the biosimilars and those classes that have those. So, thinking about the erythropoietin agents, as well as the infliximab products. And then another one might be even the hyaluronic acid agents because of the fact that there are just so many in that class, and really from a clinical perspective, they have very similar effectiveness.
Do you think the different formulary regulations proposed by CMS will help lower drug costs?
My ideal answer, I would love to see it help lower drug costs. I think that there are still some unknowns in terms of the safe harbor rule that was recently released and what is that going to do for the industry in respect to rebates and how those dollars get redistributed. I think the other thing that we are going to have to realize is that no one is mandated to do an indication-based formulary or to do a Part B step. So, if we don’t have widespread uptake by plan sponsors of these programs, I think that the benefit that we’d like to see might not be as large as we’d hope.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More